Who Converts Glucoraphanin Into Sulforaphane: Myrosinase or Your Gut Microbiome?
Picture one sealed glucoraphanin parcel sitting on a supplement label. Two possible converters are waiting for it. One is active myrosinase from a cruciferous plant. The other is a collection of enzyme functions produced by certain gut microbes.
Now picture a shopper comparing three labels: glucoraphanin alone, glucoraphanin with active myrosinase, and a formula that says the gut microbiome can do the conversion. The practical question is obvious: if the gut can convert glucoraphanin, why include active myrosinase at all?
Both Can Convert It, but Not in the Same Way
Both active plant myrosinase and enzymes produced by certain gut microbes can convert glucoraphanin. Active myrosinase can be intentionally supplied with the precursor and has produced higher and earlier average sulforaphane exposure in human studies. Microbial conversion can still occur, but it varies between people and may produce several related metabolites.
Plant myrosinase is an enzyme made by cruciferous plants. Humans do not manufacture plant myrosinase. Certain gut microbes can provide myrosinase-like or beta-thioglucosidase activity later in digestion. That makes the two routes complementary possibilities, not identical systems. Neither route guarantees the same personal conversion or absorption outcome for everyone.
Meet the Three Actors Once
Glucoraphanin: the Stable Precursor Parcel
Glucoraphanin is the relatively stable starting compound. It needs hydrolysis before sulforaphane can form.
Myrosinase: the Plant Enzyme
Myrosinase hydrolyses glucoraphanin after plant tissue is disrupted or after an active enzyme source is released from a formulation.
Microbial Myrosinase-Like Activity: the Later Converter
Certain gut microbes carry enzyme functions that may metabolise glucoraphanin later in digestion. Researchers may describe these as microbial myrosinase, microbial thioglucosidase or related glucosinolate-converting activity.
Two Routes Compete for the Same Precursor
Route A: Plant-Enzyme Express Route
- Plant tissue is disrupted or a capsule releases active myrosinase.
- Glucoraphanin and the enzyme can meet earlier in digestion.
- Sulforaphane can become available for an earlier absorption opportunity.
- Digestive conditions, release timing, enzyme activity and formulation still matter.
Route B: Microbial Relay Route
- Some glucoraphanin remains unconverted through the earlier digestive stages.
- The precursor travels further through the gastrointestinal tract.
- Microbes with relevant conversion functions may act on it later.
- Efficiency, timing and the mix of end products can differ between people.
The microbial relay is not a failed route. It is a later and more person-dependent route. Supplying active myrosinase does not erase microbial metabolism, but it can address one variable that a formulator can control.
The Conversion Handoff Timeline
- Capsule release or food disruption: the precursor and any active plant enzyme become available to meet.
- Stomach exposure: acidity, time and delivery format may affect enzyme survival and reaction conditions.
- Small-intestinal absorption opportunity: sulforaphane formed earlier may be available for absorption before the remaining precursor travels further.
- Unconverted glucoraphanin continues: the portion not converted earlier can move towards the colon.
- Colonic microbial metabolism: bacteria with relevant genes and enzyme functions may convert some of the remaining precursor.
- Blood or urinary metabolite measurement: human studies commonly estimate exposure by measuring sulforaphane and its metabolites over time.
This is a handoff, not an on-off switch. One dose can involve earlier plant-enzyme conversion, later microbial conversion, host metabolism and excretion. The proportions may differ by formulation and by person.
The 2026 Human Evidence Scoreboard
Mastaloudis and colleagues tested a glucoraphanin-rich broccoli seed extract in a randomised, double-blind, crossover study involving 16 adults. Each participant received the extract with mustard-seed myrosinase on one occasion and without supplied myrosinase on another. Both versions included ascorbic acid. Urinary sulforaphane metabolites were used to estimate bioavailability.
| Study measure | Glucoraphanin plus myrosinase | Glucoraphanin without supplied myrosinase |
|---|---|---|
| Average 24-hour bioavailability | 39.8% | 18.6% |
| Conversion measured in the first 8 hours | 25.4% | 8.0% |
| Microbiome result after the single dose | No overall difference in faecal bacterial-community measures between treatments. Four Bacteroides thetaiotaomicron glucoraphanin-converting genes were correlated with conversion in the restricted glucoraphanin-first analysis. | |
The practical signal is timing as well as average total exposure. The supplied-enzyme condition produced a larger difference in the first 8 hours, while the later 8 to 24-hour period was much closer between conditions.
Important boundaries: this study did not use Kiwi Superfoods Broccoli Sprout Powder. It used a broccoli seed extract, mustard-seed myrosinase and ascorbic acid. The percentages apply to those study conditions. They do not prove that every active-myrosinase formula doubles conversion, and they do not show that microbial conversion never works.
The Microbial Route Does Not Have One Fixed Finish Line
A 2025 Frontiers in Physiology review describes gut microbial metabolism as a network rather than a single clean endpoint. Depending on the microbial functions and conditions involved, glucoraphanin metabolism may yield:
- Sulforaphane
- Sulforaphane nitrile
- Erucin
- Erucin nitrile
- Other related compounds
This distinction matters when a study reports that glucoraphanin disappeared. Disappearance of the precursor does not prove that all of it became sulforaphane. It may have entered several metabolic branches. It also does not mean every person produces every compound on the list.
The Microbial Variability Fingerprint
| Evidence-supported influences | Consumer assumptions the evidence does not support |
|---|---|
|
|
Current research is better at showing that microbial function contributes to variation than at predicting an exact personal yield. Gene associations can help researchers understand mechanisms, but they are not yet a simple consumer score.
What the 2025 Nature Microbiology Study Adds
A 2025 Nature Microbiology trial included an exploratory microbiome analysis. A Bacteroides gene operon involved in glucoraphanin conversion, assessed through its BT2160 transcriptional regulator, was associated with serum sulforaphane concentration and response in that trial. This supports the idea that microbial functions can contribute to person-to-person variation.
The finding is interesting, but it is not a consumer instruction. The analysis was exploratory. It does not validate a retail microbiome test, prove that adding one bacterial species improves conversion, or support a probiotic recommendation. It must not be used to make a diabetes-treatment claim. The study was not a study of Kiwi Superfoods Broccoli Sprout Powder.
Supporting Human Evidence
Fahey et al. 2015
Fahey and colleagues compared standardised broccoli sprout and seed preparations with different myrosinase activity. Across the preparations studied, those retaining active plant myrosinase produced roughly three to four times greater average sulforaphane bioavailability than glucoraphanin-rich preparations without active plant myrosinase. The glucoraphanin-only route, which relied mainly on intestinal microbial activity, also showed wider person-to-person variation.
Those are study-specific averages across particular preparations and delivery formats. They should not be transferred directly to every commercial product.
Okunade et al. 2018
In a tested cooked-broccoli meal, supplying an active myrosinase source from mustard seed increased the availability of sulforaphane metabolites compared with cooked broccoli alone. This supports the general formulation principle that an active food-supplied enzyme can affect conversion. It is not a recommendation to use mustard powder as a substitute for a formulated broccoli sprout product.
Digestive-Transit Caveat
A small 2019 pilot study examined a glucoraphanin-rich broccoli sprout and seed extract with active myrosinase under different stomach-acidity and capsule conditions. The results suggest that stomach conditions and delivery format may affect co-delivered myrosinase and conversion.
The study was small and should not be treated as definitive. It is not a reason to start, stop, reschedule or change any proton-pump inhibitor, antacid or other medicine. Medication decisions belong with a doctor or pharmacist.
What the Research Does Not Let Us Say
It does not. Enzyme activity, release, digestion, absorption and host metabolism still vary.
It does not bypass the gastrointestinal tract, and later microbial metabolism can still matter.
Human studies show that microbial conversion can occur, although timing and efficiency vary.
Current human evidence does not support a probiotic prescription for predictable sulforaphane yield.
They do not. The cited trials used different materials, doses and study conditions.
Why We Do Not Leave the Whole Conversion Job to the Gut
Kiwi Superfoods Broccoli Sprout Powder combines the precursor and active plant enzyme rather than relying solely on microbial conversion. The current product page describes:
- 100% NZ-grown, lightly milled broccoli sprouts
- Air-drying intended to preserve active myrosinase
- Guaranteed glucoraphanin
- Active myrosinase
- Independent testing for glucoraphanin and myrosinase activity
- Two 600 mg capsules per daily serve
- A guaranteed minimum 6 mg sulforaphane per daily dose
The formulation decision is about controlling one variable: supplying active plant myrosinase with glucoraphanin. It does not mean the microbiome is completely bypassed, digestion no longer matters, or every person converts and absorbs the same amount. The stated 6 mg is a product specification, not a promise that every individual absorbs 6 mg. The product was not used in the cited 2026 trial and should not be expected to reproduce its percentages.
The Three-Question Label Decision
-
What precursor or end compound is quantified?
Check whether the label states glucoraphanin, sulforaphane, or a calculated potential amount. These are not interchangeable. -
Is active myrosinase present and tested?
A named enzyme source is useful, but evidence of activity and testing is more informative than ingredient presence alone. -
What does any stated sulforaphane number represent?
Ask whether it is measured sulforaphane, a guaranteed formulation specification, or a theoretical conversion value. It should not be read as a guaranteed absorbed dose.
Frequently Asked Questions
Does the gut microbiome convert glucoraphanin into sulforaphane?
Yes. Certain gut microbes have myrosinase-like or thioglucosidase activity that can convert some glucoraphanin later in digestion. The amount and timing vary between people.
Is plant myrosinase more reliable than gut bacteria?
Active plant myrosinase is a controllable formulation input and has produced higher and earlier average sulforaphane exposure in human studies. It still does not guarantee a personal conversion result.
Do humans produce myrosinase?
No. Humans do not produce the plant enzyme myrosinase. Conversion without active plant myrosinase depends mainly on microbial enzyme functions and other digestive factors.
What happens if a supplement contains glucoraphanin but no active myrosinase?
Some glucoraphanin may reach the colon and be converted by gut microbes. Human studies show that this route can work, but average conversion is often lower and more variable under the tested conditions.
Can plant myrosinase and gut microbes both contribute to conversion?
Yes. Active plant myrosinase can act earlier, while unconverted glucoraphanin may travel further and become available for later microbial metabolism.
Why do different people convert different amounts of glucoraphanin?
Relevant microbial genes, community composition, digestive timing, formulation, starting compound and host differences can all contribute to variability.
Which bacterial genes are linked with glucoraphanin conversion?
The 2026 study linked Bacteroides thetaiotaomicron genes BT2156, BT2157, BT2158 and BT2159 with conversion in a restricted analysis. A 2025 exploratory study also assessed the BT2160 regulator of the related operon.
Can a microbiome test predict sulforaphane conversion?
Not with validated personal precision at present. Research gene associations are not the same as a consumer test that can forecast an exact sulforaphane yield.
Does active myrosinase bypass the gut microbiome?
No. It can provide an earlier conversion route, but digestion, absorption, remaining glucoraphanin and later microbial metabolism can still differ between people.
Does one dose of glucoraphanin change the microbiome?
The 2026 single-dose study found no overall difference in measured faecal bacterial-community patterns between the two treatment conditions. That does not answer what repeated intake may do.
Can gut microbes produce compounds other than sulforaphane?
Yes. Research describes sulforaphane nitrile, erucin, erucin nitrile and other related compounds as possible microbial outcomes. Not every person produces every compound.
What should a sulforaphane supplement label say about conversion?
It should clearly distinguish the quantified precursor or end compound, state whether active myrosinase is present and tested, and explain what any sulforaphane number represents.
References
- Mastaloudis A et al. 2026. Exogenous myrosinase from mustard seed increases bioavailability of sulforaphane from a glucoraphanin-rich broccoli seed extract in a randomized clinical study. Scientific Reports.
- Dmytriv TR, Lushchak O, Lushchak VI. 2025. Glucoraphanin conversion into sulforaphane and related compounds by gut microbiota. Frontiers in Physiology.
- Dwibedi C et al. 2025. Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes. Nature Microbiology.
- Fahey JW et al. 2015. Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase. PLOS ONE.
- Okunade O et al. 2018. Supplementation of the diet by exogenous myrosinase via mustard seeds to increase sulforaphane bioavailability after cooked broccoli. Molecular Nutrition and Food Research.
- Fahey JW et al. 2019. Bioavailability of sulforaphane following glucoraphanin-rich broccoli sprout and seed extracts with active myrosinase. Nutrients.
Next Steps
For more label context, read choosing a glucoraphanin supplement. For the plant-side background, see broccoli shoots and sulforaphane formation and why three-day-old broccoli sprouts matter.
To explore the wider evidence without losing sight of realistic boundaries, continue with sulforaphane and Nrf2, the broccoli sprout extract evidence guide, or browse the broccoli sprouts collection.
Concentrated broccoli sprout products may not suit everyone. Seek qualified advice before use during pregnancy or breastfeeding, for children, with thyroid conditions, regular medicines, planned surgery or complex health conditions.
